The Pathology of Neoplastic Diseases 2024 — On Demand

Thursday, May 2, 2024, 8:00 AM - Tuesday, September 30, 2025, 12:30 PM

We're pleased to offer an on demand option for the The Pathology of Neoplastic Diseases 2024 course, originally held live from April 29 to May 3, 2024.

Expert faculty provide a comprehensive and up-to-date review of the pathology in selected sub-specialty areas of neoplastic disease, with this year's program focusing on Genitourinary, Gastrointestinal, and Thoracic pathology. The lectures incorporate the appropriate use of advanced diagnostic techniques, such as immunohistochemistry and molecular pathology, and include the assessment of therapeutic biomarkers. View the brochure from the live program to see a complete list of lectures available in this on demand offering.

Additionally, the Slide Seminars from the live course are available for purchase, including:

• Uncommon and Rare Esophageal Tumors
• Thoracic Teaching Cases To Tease your Brain
• Interesting Cases in GU Pathology

The Department of Pathology at Memorial Sloan Kettering Cancer Center has produced this course for 40 years, continuously expanding its scope to reflect the increasing contributions of cytopathology, immunopathology, and molecular pathology. The course faculty includes attending pathology staff from Memorial Sloan Kettering Cancer Center, along with selected visiting lecturers.

Please note that if you do not wish to purchase the full course on demand, you can purchase the selected sub-specialties individually:

• Gastrointestinal Pathology
• Thoracic Pathology
• Genitourinary Pathology

This course is designed for practicing pathologists in both academic and private practice settings, as well as residents and fellows in pathology who wish to broaden their understanding of neoplastic diseases.

1. Label current classifications and diagnostic criteria for tumors and tumor-like lesions
2. Highlight the appropriate use of ancillary diagnostic techniques
3. Discuss differential diagnoses and understand the practical, problem- oriented approach
4. Identify clinical pathological features of the various tumor entities

Upon successful registration, access to the course materials, including instructions for claiming credit, is located under the 'Course Content' tab. For those that purchase this on demand, access to the content, as well as the opportunity to claim credit, is available through September 30, 2025.

On Demand Access Fees

• Physicians (MDs, PhDs, and DOs): $1,100

• Residents, and Fellows: $750

• Registrants in Low-and Lower-Middle-Income Countries: Complimentary

• MSK Employees: Complimentary

Slide Seminars (Optional Add-on Fee)

• Gastrointestinal Pathology: $50

• Thoracic Pathology: $50

• Genitourinary Pathology: $50

Registrants that Reside and Practice in Low & Lower-Middle Income Countries: We are pleased to offer complimentary registration to registrants residing in low and lower-middle income countries as defined by The World Bank. If you qualify for complimentary registration, please submit a request here for a complimentary promotion code to use at registration.

MSK Alumni and MSK Cancer Alliance Member Discount: A discounted registration rate is offered to MSK Alumni and MSK Cancer Alliance members for all CME programs at MSK. If you belong to either of these groups, please submit your request here to receive a promotion code to be applied at registration.

MSK Employees: MSK employees can register for any CME program on a complimentary basis. Employees need to log in to the MSK CME Portal using their SS0 login credentials and register for the desired program. We kindly request that those who register also plan to attend. If you are registered for this program and unable to attend, please notify us by emailing [email protected].

Please note that after your payment has been processed, no further promotional discount adjustments will be made to your registration.

This Memorial Sloan Kettering Continuing Medical Education on demand program is non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 28.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABPath CC Recognition Statement

This activity will offer 28.50 Lifelong Learning (CME) credit towards the American Board of Pathology’s Continuing Certification program.

Recorded/Review Date: April 29-May 3, 2024 | Original Release Date: May 2, 2024 | Termination Date: September 30, 2025

MSK Course Director 

Meera R. Hameed, MD
Chief, Surgical Pathology Service



MSK Course Co-Directors 

Victor E. Reuter, MD
Director, Genitourinary Pathology

Jinru Shia, MD
Director, Gastrointestinal Pathology

William D. Travis, MD
Director, Thoracic Pathology

 

Invited Faculty 

Sanja Dacic, MD, PhD
Yale School of Medicine 

Gregory Lauwers, MD
Moffitt Cancer Center

Rohit Mehra, MD
Michigan Medicine (UMICH) 


MSK Department of Pathology and Laboratory Medicine Faculty 

Narasimhan P. Agaram, MBBS
Hikmat A. Al-Ahmadie, MD
Marina K. Baine, MD, PhD
Olca Basturk, MD
Darren J. Buonocore, MD
Jason C. Chang, MD
Yingbei Chen, MD, PhD
Jie-Fu (Jeff) Chen, MD
Samson W. Fine, MD
Anuradha Gopalan, MD
Raymond A. Isidro, MD, PhD
Rohan Mittal, MD
Natasha Rekhtman, MD, PhD
Benzion Samueli, MD
Judy Sarungbam, MD
Jennifer L. Sauter, MD
Carlie Sigel, MD
Amitabh Srivastava, MBBS
Laura H. Tang, MD, PhD
Satish K. Tickoo, MD
Efsevia Vakiani, MD, PhD
Jacob Valk, MD
Soo-Ryum (Stewart) Yang, MD

 

View relevant financial relationships as of the program recording date, here.

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.